Categories: NewsPharmaceutical

AllSci Launches AI Development Partner Program to Accelerate Pharmaceutical and Biotechnology R&D

Exclusive Early Access to AllSci’s Groundbreaking Scientific AI Platform

NORTH BETHESDA, Md., Jan. 23, 2025 /PRNewswire/ — AllSci has opened its Development Partner Program to R&D-driven life science organizations seeking to leverage the power of its revolutionary AI platform. This exclusive program offers early access to AllSci’s proprietary pharmaceutical hypothesis database, advanced visualization engine, and AERIS—AllSci’s cutting-edge AI purpose-built for research and scientific knowledge discovery.

Program partners will collaborate closely with AllSci to derive data-driven insights that inform their portfolio strategies, uncover R&D opportunities and gaps, and empower their researchers with tools to improve their efficiency, knowledge, and workflows.

Why Partner with AllSci?

AllSci’s proprietary AERIS AI extracts research hypotheses, gathers supporting and refuting evidence from the literature, and visualizes the evolution and context of related science over time.

By joining the Development Partner Program, pharmaceutical and biotechnology organizations gain exclusive entry to AERIS and other transformative R&D tools.

  • Access Hypotheses: Explore science through supported and refuted hypotheses in addition to traditional articles and abstracts.
  • Identify Gaps and Opportunities: Map the scientific landscape through embedding visualizations that highlight research gaps and opportunities.
  • Benchmark: Analyze the research ecosystem, including concepts, organizations, and individual contributors.
  • Find Collaborators: Map collaboration networks and connect with the right potential partners.
  • Optimize Portfolio: Gain insights into molecules and technologies within the R&D pipeline.

A Game-Changer for Pharma and Biotech

“AllSci’s technology transforms how pharmaceutical and biotech companies understand the R&D landscape, improves their research productivity, and helps them differentiate their portfolios and strategy” said Matthew Chervenak, Founder and CEO of AllSci. 

Secure Your Spot

Pharmaceutical and biotechnology organizations are invited to explore this opportunity to redefine their approach to research. Participation in the Development Partner Program is limited.

For more information and to apply, please email us at development@allsci.com

About AllSci 
AllSci reframes how scientific knowledge is created, shared, and measured. Through AllSci, researchers and organizations explore and evaluate the scientific literature, publish their ideas and experimental results, and measure their contributions to the scientific dialogue. The company’s proprietary AI-driven technology atomizes and connects scientific knowledge, creating new ways to visualize, explore, and track information. AllSci envisions a world in which researchers and organizations maximize their contributions to science and society.

Media Contact:
Dr. Eva Szarek, PhD
Director of Marketing
eszarek@allsci.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/allsci-launches-ai-development-partner-program-to-accelerate-pharmaceutical-and-biotechnology-rd-302358816.html

SOURCE AllSci

Staff

Recent Posts

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers…

14 minutes ago

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

11 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

14 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

14 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

14 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

14 hours ago